Open AccessA phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
Author(s) -
Soon Jae Hwang,
Beom Hee Lee,
Woo-Shik Kim,
DaeSeong Kim,
Chong Kun Cheon,
Chang Hwa Lee,
Yunha Choi,
Jin-Ho Choi,
Ja Hye Kim,
Han-Wook Yoo
Publication year - 2022
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000030345
Subject(s) - medicine , fabry disease , beta (programming language) , clinical trial , multicenter study , open label , adverse effect , disease , randomized controlled trial , computer science , programming language